Advertisement

Topics

J&J's ERLEADA Lowered Risk of Death in Patients with Non-Metastatic Prostate Cancer

11:30 EST 15 Feb 2018 | Drug Discovery Development

The Janssen Pharmaceutical Companies of Johnson & Johnson announced new findings from the Phase 3 SPARTAN clinical trial that showed treatment with ERLEADA, an investigational, next-generation androgen receptor inhibitor, decreased risk of metastasis or death by 72 percent.
Contributed Author: 
Johnson&Johnson

Original Article: J&J's ERLEADA Lowered Risk of Death in Patients with Non-Metastatic Prostate Cancer

NEXT ARTICLE

More From BioPortfolio on "J&J's ERLEADA Lowered Risk of Death in Patients with Non-Metastatic Prostate Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...